

Regulations of The European Federation for Medicinal chemistry and Chemical biology (EFMC)

Regulations approved at the EFMC-Council meeting held in Zagreb, Croatia on September 3, 2023. The European Federation for Medicinal Chemistry is an Association under Swiss Law, pursuant to Articles 60 et seq. of the Swiss Civil Code with domicile in Bern (c/o Swiss Chemical Society, Laupenstrasse 7, 3008 Bern).

The Regulations of the EFMC consist of Statutes and of By-Laws.

Statutes of EFMC

A. Objectives and Means of the Federation

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC, hereinafter referred to as the Federation) is a voluntary, independent association representing Medicinal Chemistry & Chemical Biology Societies in Europe. Its objective is to advance the science of Medicinal Chemistry and Chemical Biology by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders. It pursues these objectives mainly by the following means:

- 1] By holding or assisting in the holding of the biennial "EFMC International Symposium on Medicinal Chemistry" (EFMC-ISMC), other scientific meetings, schools and working-groups, in order to exchange ideas and information, and to encourage discussions relating to Medicinal Chemistry and Chemical Biology.
- 2] By co-operating on scientific issues with other organisations related to Medicinal Chemistry and Chemical Biology.
- 3] By instituting and conferring awards related to the objectives of the Federation.
- 4] By collecting and disseminating relevant information on the activities of the member societies.
- 5] By promoting publications in the fields of Medicinal Chemistry and Chemical Biology.
- 6] By establishing and observing By-Laws.
- 7] By following any other course of action which is in accordance with the objectives of the Federation.

B. Membership

- 1] Categories of membership
-) Adhering Organisations; these are scientific organisations within the European sphere, active in Medicinal Chemistry and related fields.

2] Admission and Termination

-) Upon application, membership is granted by the Executive Committee (EC) and approved by the Council. As a general rule, an entrance fee is due.
-) The membership of an Adhering Organisation terminates, when:
 - a) it is dissolved
 - b) it notifies its withdrawal in writing to the Secretary of the Federation at least three months before the end of the calendar year
 - c) it has not paid the annual dues for three consecutive years.

3] Duties of Adhering Organisations

-) Support the objectives of the Federation.
-) Pay the annual dues prior to the annual meeting of the Council.
-) Submit on a regular basis relevant information concerning one's own activities to the Secretary.
-) Publicise on a regular basis the activities of the Federation, including distribution of the EFMC publications, to the individual members of the Adhering Organisation.

C. Organisation and Management

1] The affairs of the Federation shall be conducted by a Council through an Executive Committee (EC).

2] The Council

2.1] The Council consists of the members of the EC and one delegate of each Adhering Organisation. The voting rights are allotted according to the following rules:

| | |
|--|----------|
| members of the EC | 1 vote |
| countries with up to 99 members: | 2 votes |
| countries with 100-199 members: | 3 votes |
| countries with 200-399 members: | 4 votes |
| countries with 400-599 members: | 5 votes |
| countries with 600-899 members: | 6 votes |
| countries with 900-1199 members: | 7 votes |
| countries with 1200-1599 members: | 8 votes |
| countries with 1600-1999 members: | 9 votes |
| countries with 2000-2499 members: | 10 votes |
| countries with 2500-2999 members: | 11 votes |
| countries with more than 3000 members: | 12 votes |

As for countries with more than one Adhering Organisation, votes will be proportionally distributed among them, taking into account their respective memberships. The resulting number will be rounded off to the closest digit. In the distribution process, each NAO will receive at least one vote.

- 2.2] Unless explicitly stated otherwise in these regulations, the Council will decide on any matter by simple majority of votes.
- 2.3] 40 % of members representing at least 40 % of voting rights constitute the quorum necessary to take decisions with financial consequences.
- 2.4] During each Council Meeting, the Council is presented with the final accounts of the federation for the previous year, audited by an agreed auditor (As per point 3.9). The council will officially approve the presented accounts & auditor report, discharging by this process the Treasurer of his responsibilities.
- 2.5] Voting rights are reserved to delegates or their deputies (see below) of those Adhering Organisations, which have paid their annual fees.
- 2.6] The names of the delegates must be formally communicated to the Secretary by the corresponding Adhering Organisation; also any change in delegation has to be formally communicated in the same way.
- 2.7] Prior to the meeting, each delegate may nominate in written form a deputy from the same organisation to attend meetings and to vote on his or her behalf.
- 2.8] The Council will meet at least once per annum, every other gathering taking place on the occasion of the concomitant EFMC-ISMC. At these meetings the President will report on the activities of the EC and seek the approval of the Council.
- 2.9] Persons invited by the EC can participate in the meetings of the Council as observers.
- 2.10] An invitation to the meeting and the final agenda will be circulated to the Council members and all Adhering Organisations at least one month before the meeting.
- 2.11] An extraordinary meeting of the Council must be convened at the request of at least 40 % of the delegates.

3] The Executive Committee (EC)

- 3.1] The EC shall manage all the business and affairs of the EFMC. The EC consists of seven members: the President, the President Elect or the Past President, the Secretary, the Treasurer, and three additional members.
- 3.2] In order to keep an appropriate balance between Industry and Academia, a minimum of 2 members of the EC must belong to each sector. Furthermore, a minimum of 2 members of the EC must belong to either gender.
- 3.3] Members of the EC are not delegates of their respective countries.
- 3.4] Four members of the EC constitute the quorum necessary to take decisions. The decisions shall be taken by simple majority of votes of the members attending the meeting. In case of a draw, the president casts the deciding vote.
- 3.5] The EC shall decide all question of interpretation of the Statutes, By-laws and Regulations
- 3.6] The President

-) Is the legal representative of the Federation, who negotiates with other organisations. The President may authorise, in written form, another member of the EC to represent him or her in such duties.
-) Is responsible for coordinating the activities and affairs of the Federation and shall survey all activities of the EC.
-) Will call and chair the EC - and Council- meetings of the Federation.
-) Will sign contracts on behalf of the Federation, after the approval by the EC.

3.7] The President Elect and the Past President assist the President in his or her activities and may deputise for him whenever necessary.

3.8] The Secretary

-) Keeps record of all members of the Federation and their respective delegates.
-) Takes care of all reports of the EC- and the Council-meetings.
-) Keeps the archives of the Federation.
-) Distributes the agenda for the meetings of the Council and the EC at least one month prior to such meetings.
-) Collects and distributes information relevant for the objectives of the Federation within the members of the Federation.
-) Assists the President in his/her duties.

3.9] The Treasurer

-) Maintains the accounts and oversees the finances of the Federation.
-) Sends out the invoices to pay the annual dues not later than Feb. 28.
-) Keeps a record of all financial transactions of the Federation.
-) Strives to increase the financial resources of the Federation.
-) Renders a complete Financial Account at each annual Council Meeting.
-) Solicits an audit by a legally authorised auditor prior to each annual Council Meeting. The auditor is proposed by the treasurer and has to be approved by the Council.
-) Submits a budget to the EC for approval not later than December. 1. Any major deviation from the budget will require the approval of the EC prior to the expenditure.

3.10] Further Tasks Among its members, the EC will assign the responsibilities of International Liaison, Communication and Planning.

4] Temporary Working Groups and Teams

4.1] Temporary Working Groups and Teams to pursue specific activities can be established and later dissolved by the EC. The formal approval of creation and dissolution will be submitted to the Next ordinary Council Meeting.

4.2] The composition of the working groups and teams is flexible. The EC appoints the members based on a good balance in expertise, gender, country and academia/industry.

4.3] The leader of the working group or team reports regularly at the EC-meetings and the Council meeting.

4.4] Activities and budget proposed by the working groups and teams are subject to a formal approval by the EC and are regarded provisional till the final approval by the Council.

5] Advisory Board (AB)

5.1] An Advisory Board can be established and later dissolved by the EC. The formal approval of creation and dissolution will be submitted to the next ordinary Council Meeting.

5.2] The AB consists of 5-7 members nominated by the EC and should have members from both industry and academia. Terms of AB members are 3 years and are subject to renewal by the EC.

5.3] The AB is chaired by the Past President. The chair reports regularly at the EC-meetings and the Council meeting.

5.4] The budget for the AB will be fixed every year according to the financial situation and a financial report will be filed each year by the chair.

D. Election and terms of members of the Executive Committee

1] All members of the EC, except the President and the Past President, are elected by secret ballot by the Council during a meeting of the Council. In case an Adhering Organisation is not represented by a delegate at the meeting, votes will be accepted by a letter addressed to the Secretary signed by the delegate and countersigned by the president of the Adhering Organisation. The candidate obtaining the relative majority of votes is elected. In case of a draw, a second ballot between those candidates with equal votes is performed, in this case not considering the votes received by mail. In the case of a second tie, a coin will be used to select the corresponding EC member.

2] After a term of one year, the President Elect will automatically become President.

3] The members of the EC will serve for a period of two years and may be re-elected for a maximum of two additional and successive terms. This limitation does not apply when an EC-member is elected as President Elect. The one-year term of President Elect will be followed automatically by another of three years as President. The outgoing President will automatically become Past President for a two-years term.

4] Three months ahead of the meeting at which the election takes place, the Secretary will formally invite all Adhering Organisations to nominate candidates for vacant positions. Nominations made by Adhering Organisations have to be received within one month in written form by the

Secretary and have to be signed by the corresponding president. EFMC encourages gender diversity among candidates, and stimulates all Adhering Organisations to take this into account while nominating candidates. All candidates have to formally accept their candidacy by providing a signed letter of acceptance to the Secretary. The Secretary will include all nominations in the agenda of the Council-meeting where the elections will take place.

- 5] In addition to the nominating organization, candidacies must be supported by a minimum of three Adhering Organisation from three different countries. In addition to the nominating organization, candidacies for President Elect must however be supported by at least five Adhering Organisations. The EC has also the right or - if no candidates are proposed, the duty - to nominate candidates for any position, especially taking into consideration the right balance between Industry and Academia and reflecting the EFMC commitment for gender balance.
- 6] EC-membership is restricted to one person per country. The country of an EC member is defined as the country of the nominating Adhering Organisation. Several candidates for EC members from the same country will be accepted. Voting will start by the President Elect, followed by the Secretary, the Treasurer and the rest of the EC members. Each position of the EC will be voted sequentially checking after each round the compliance to the rules regarding the Country of origin and the Academia/Industry balance. Candidates, whose election would break these rules will be excluded from the next round of election.
- 7] When an EC vacancy occurs in the period between elections, the EC will reorganise to cover the corresponding tasks and a new member will be elected at the next Council meeting
- 8] The EC can be recalled in an ordinary Council meeting by absolute majority of the total voting rights. For this, a quorum of at least 40% of Council members is necessary.
- 9] If the EC resigns during its normal period of office, the Council will immediately nominate 3 members to organise elections.

E. Finances

- 1] Each Adhering Organisation is obliged to pay to the Federation annual dues based on the number of members in their local organisation or in the section of the same organisation concerned with Medicinal Chemistry and/or Chemical Biology.
- 2] The EC has the competence to ask for fees from schools / meetings organised under the auspices of EFMC.
- 3] Dues indicated under 1] and 2] are fixed in the form of By-Laws.
- 4] All income and assets of EFMC will be employed solely towards the promotion of the objectives of the Federation.
- 5] In the frame of the yearly budget, the EC has the competence to refund to its members the expenses due to their engagement in EFMC activities, including Secretary work, which are not refundable by other institutions. This includes communication in general and with the adhering societies in particular, issuing of newsletters, other printing material and their distribution; travel expenses of EC members in EFMC mission, for the attendance of EC meetings, and visits to adhering societies or joint meetings with co-operating organisations.
- 6] Adhering Organisations are responsible for the expenses related to sending their delegates to

Council meetings.

F. Amendment of the Statutes

- 1] The Statutes of the Federation can solely be amended at a regular meeting of the Council by absolute majority of total voting rights of the Federation. For this, a quorum of at least 40% of the Council members is necessary. Modification proposals may be submitted by the EC or by at least three Adhering Organisations from three different countries to the Secretary, who will include them in the agenda of the next Council meeting.
- 2] The By-Laws of the Federation can solely be amended at a regular meeting of the Council by absolute majority of voting rights present in the meeting. For this, a quorum according to C 2.3 is necessary. Proposals may be submitted by the EC or by at least two Adhering Organisations from two different countries to the Secretary, who will include them in the agenda of the next Council meeting.
- 3] In case of lack of a quorum, the unchanged proposal will be presented on the next ordinary meeting of the Council. There the decision will be made on basis of absolute majority of the voting rights present in the meeting, without the need of a distinct quorum.
- 4] In situations for which the regulations do not give a provision, the EC will act according to the best of its knowledge.

G. Dissolution

- 1] For the dissolution of the EFMC a majority of two thirds of the total voting rights of the Council is required.
- 2] If after settlement of all debts and liabilities any properties or assets remain, these will be given to another institution having objectives similar to those of EFMC.

H. Liabilities

- 1] The liabilities of the EFMC shall be limited to the assets of the Association.

EFMC By-laws

A. Membership Application

Scientific Organisations applying for membership need to fulfil the following criteria:

- 1] They are a legal entity as Scientific Organisation in a country within the European Sphere or are a section of such a Scientific Organisation.
- 2] They are active in the field of Medicinal Chemistry or related fields.
- 3] In case an organisation of the country is already member of the EFMC, a statement on the differences between the two organisations is required.
- 4] A representative of an applying organisation is invited as observer to the Council meeting where the

application has to be approved. There he/she introduces the objectives and means of the organisation to the Council.

B. Relationships with related Scientific Bodies:

- 1] The Federation co-operates with other national and international scientific bodies that have a direct interest in Medicinal Chemistry and Chemical Biology. Such co-operation may take the form of active discussions, representation on committees, the participation in joint meetings, or any other related activity that furthers the interests of the Federation.
- 2] On the basis of reciprocity, the Federation will invite related scientific organisations to organise sessions on EFMC meetings. These sessions will be organised under the rules and full responsibility of the organiser of the EFMCmeeting.
- 3] On basis of reciprocity, the Federation will invite representatives of related scientific organisations as observers on their regular Council meetings.
- 4] Actions given under 2] and 3] need approval of the Council by simple majority of voting rights. The current status of relationships is given in the Annex of the Regulations.

C. Corporate Members

-) Corporate Members are Pharmaceutical, Biotechnology/Biopharma companies with medicinal chemistry divisions, CROs, Service Providers, Publishers that actively partner with EFMC in a number of ways. Corporate Membership can be achieved by sponsoring an EFMC International Symposium, by sponsoring an official EFMC Award, by paying an annual fee. Respective minimum dues are fixed in the by- laws.

D. Finances

- 1] The annual contribution amounts to 2,5€ per member. Payments are expected prior to each annual meeting of the Council. All Adhering Organisations, who do not fulfill this obligation, lose their voting rights.
- 2] The entrance fee for new Adhering Organisations amounts to one annual contribution.
- 4] Each local Organizing Committee of EFMC sponsored schools will pay to EFMC a contribution of 3 € per participant. Sponsorship is granted under the conditions given in section E. Current EFMC-Schools are listed in the Annex of the Regulations.
- 5] Events sponsored by EFMC and that apply a registration fee to the participants will pay to EFMC a contribution of 500€ for events up to 200 participants, 1000€ for events between 200 and 750 participants and 2000€ for events above 750€. The contribution is waived for events organized by an Adhering Organisation.
- 6] In general, no refunds for travelling and accommodation expenses will be paid to the delegates of ordinary and extraordinary Council meetings. In case of particular circumstances, the EC may decide to assist Council members to participate in regular annual meetings.

E. The EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC)

- 1] The EFMC has started the organisation of a bi-annual series of symposia under the title 'EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC). The symposia take place in even years in either the late summer or early fall in a country of the EFMC sphere.
- 2] The organisation of an EFMC-ISMC is commissioned on decision of the Council to one or more Adhering Organisations. Adhering Organisations may apply as organisers by sending a proposal to the EC after publication of a call.
- 3] The organizing Adhering Organisation(s) propose(s) an International Organising Committee (IOC) in which the EFMC President will participate. The IOC has to be approved by the EC.
- 4] The IOC is responsible for the programme and organisation of the given EFMC-ISMC; the EFMC President, who represents the EC in this committee, will report on a regular basis to the EC on the progress and contents of the programme.
- 5] The IOC takes care of the arrangements made by EFMC with related scientific organisations.
- 6] The organizing Adhering Organization(s), present a budget to the EC, at the latest 18 months ahead of the dates of the Symposium.
- 7] The organizing Adhering Organisation(s) will make sure that the Symposium budget will pay to the EFMC at least a contribution as outlined in the general conditions for hosting an EFMC-ISMC (provided in the appendix)
- 8] The financial settlement of an EFMC-ISMC should be available within one year after that EFMC-ISMC; it needs the approval of the EC.

F. Sponsoring of Scientific and Educational Events

- 1] The organisers of scientific events or post-graduate educational activities related to Medicinal Chemistry and Chemical Biology may apply for official EFMC sponsorship by formally asking for it to the EFMC Secretary (preferably by e-mail), at least three months prior to the event.
- 2] The application has to include information on:
 - Organisers
 - Dates and place
 - Program
 - Registration conditions and fees
 - Language
- 3] Sponsorship approved by the EC is depending on the following conditions:
 - Minimum duration of one full day.
 - Relevance and quality of the program.
 - International participation and the use of the English language.
- 4] The granting of the EFMC sponsorship implies:

- Place EFMC logo on the conference website and on other relevant publications
- Present a slide at the opening of the conference
- Add a page on EFMC in the book of abstracts
- Right for EFMC to distribute promotional material (Yearbooks, flyers) at the event.
- Deliver the list of attendees, including email addresses if the organizers have obtained the prior approval of the delegates (to be compliant with GDPR). EFMC therefore requests the organizers to put a procedure in place which ensures that each participant has given clear consent about the use, by EFMC, of its personal data information. As before, EFMC will use these addresses only for information on activities of EFMC.
- Payment of the corresponding fee to the EFMC by the organisers (see section D of the By-laws).

5] The symposium organiser may also apply for EFMC bursaries to assist young scientists to attend the meeting. These bursaries have to be refunded to EFMC, when the symposium closes with a benefit.

G. Awards

- 1] EFMC is conferring Awards in order to acknowledge outstanding achievements in the field of Medicinal Chemistry.
- 2] The Awards are conferred biennially, during the Opening Ceremony of the EFMC-ISMC, and consist of a diploma and a financial reward. The Awardees are invited to present a lecture during a plenary session of the EFMC-ISMC.
- 3] For each Award, the EC is responsible for the final selection of the recipient upon proposal of the corresponding Award Nomination Committee (ANC). The members of the Award Nomination Committees are designated by the EC upon proposal of the President, and in accordance with the specific Award Regulations.
- 4] The EFMC-Awards currently include:

The **Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology** established by the Prof. Dr. W.Th. Nauta Foundation to honour the memory of Prof. Dr. W. Th. Nauta, whose activities have been very important for the advancement of Medicinal Chemistry in general, and for the development of international organisational structures for this discipline. The Award is given for outstanding achievements in the field of Medicinal Chemistry and Chemical Biology to a scientist without restriction regarding nationality. In exceptional cases the Award will acknowledge contributions fostering the cooperation among medicinal chemists in Europe

The **UCB – Ehrlich Award for Excellence for Medicinal Chemistry**, established by UCB S.A. Pharma Sector, to acknowledge and recognise outstanding research in the field of Medicinal Chemistry in its broadest sense. It will be given to a young scientist without restrictions regarding nationality.

The **Prous Institute – Overton and Meyer Award for New Technologies in Drug Discovery**, established by Prous Institute, to encourage innovation and investigation with respect to technological developments related to drug discovery. It will be given to a scientist without restrictions regarding nationality.

The **EFMC-WuXi AppTec Award for Excellence in Chemical Biology**, established by WuXi AppTec, to recognise outstanding research in the field of chemical biology as defined by EFMC in **The Chemical Biology-Medicinal Chemistry Continuum: EFMC's Vision**¹, *ChemBioChem* 2021, 22, 2823-2825. It will be given to a scientist without restrictions regarding nationality.

Details of the specific regulations can be found in the Annex under “Award Regulations”

5] The creation of new EFMC Awards requires the approval by a simple majority of the Council

H. Prizes

1] EFMC is conferring Prizes in order to acknowledge and recognize outstanding young medicinal chemists (≤ 12 years after PhD) working in industry or academia within Europe. In accordance with the EFMC core values of equal opportunities and inclusiveness; Maternity leaves, as well as leaves taken for health or private reasons are considered in the ≤ 12 years after PhD limit.

2] The Prizes are given annually and consist of a diploma, € 1.000 and an invitation for a short presentation at an EFMC symposium. Two runners-up will also be identified and acknowledged.

3] The Prize Selection Committees will be appointed by the Executive Committee (EC) of EFMC, and will be chaired by an EC member. Members of the Prize Selection Committee will not participate in the review of any candidates from their own organisations, or of candidates with whom they have any relationship. The Prize Selection Committee will select the winner and two ‘runners up’.

4] The EFMC Prizes currently include:

The EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry, initiated by the former EFMC Industrial Liaison Committee (ILC) to acknowledge and recognize an outstanding young medicinal chemist (≤ 12 years after PhD) working in industry within Europe.

The EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Academia, established by the European Federation for Medicinal Chemistry to acknowledge and recognize an outstanding young medicinal chemist (≤ 12 years after PhD) working in academia within Europe.

I. Grants

EFMC is funding grants for EFMC organised events with the aim to support the participation of young academic scientists. Upon application, **a limited number of full registration fees** for EFMC-ISMC, EFMC-ASMC, EFMC-ISCB, ACSMEDI-EFMC Medicinal Chemistry Frontiers and up to 50% of the registration fee for the EFMC Short Courses or the EFMC Certified School will be covered by EFMC.

Applications should reach the Administrative Secretariat (administration@efmc.info) at least six weeks prior to the event and should consist of a CV and a short motivation letter.

J. EFMC Recognition Programme - EFMC Honorary Fellows

1] The EFMC is conferring the title of “Honorary Fellow” to recognize individuals who provided outstanding support to EFMC and contributed to strengthening the position of medicinal chemistry, or related fields, in Europe.

2] Recognitions will be given annually and will consist of: A life-long title as “EFMC Honorary Fellow”, a medal & a free registration to the event during which the ceremony will take place (EFMC-ISMC or EFMC-ASMC).

3] Nominations can be made at any time but a call will be launched in winter for candidates to be recognized at the following EFMC-ISMC or EFMC-ASMC meeting. Nomination requires submitting a dossier including:

- a. Statement of the documented facts supporting the nomination, summarizing scientific achievements and support of EFMC activities (maximum two pages).
- b. A brief curriculum vitae of the nominee.
- c. Not more than two seconding nomination letters.

4] The review committee will be composed of the current EFMC President, the Past-President/President-Elect and an adviser experienced in EFMC matters

EFMC Regulations – APPENDIX

(Status of September 4, 2022)

A. Members

- Medicinal Chemistry Section of the Austrian Chemical Society, (Austria)
- Medicinal Chemistry Division of the Société Royale de Chimie, (Belgium)
- Medicinal and Bioorganic Chemistry Division of the Royal Flemish Chemical Society (Belgium)
- Organization Pharmaceutical Research Institute (Bosnia & Herzegovina)
- Medicinal Chemistry Section of the Croatian Chemical Society (Croatia)
- Section of Synthetic Drug of the Czech Pharmaceutical Society (Czech Republic)
- The Danish Society for Medicinal Chemistry and Chemical Biology (Denmark)
- Finnish Pharmaceutical Society (Finland)
- Chemical Biology group of the French Chemical Society (France)
- Société de Chimie Thérapeutique (France)
- Division of Medicinal Chemistry of the German Chemical Society (Germany)
- Section of Pharmaceutical/Medicinal Chemistry of the German Pharmaceutical Society (Germany)
- Hellenic Society of Medicinal Chemistry (Greece)
- Organic and Medicinal Chemistry Division of the Hungarian Chemical Society (Hungary)
- Medicinal and Biological Chemistry Division of the Institute of Chemistry of Ireland (Ireland)
- The Medicinal Chemistry Section of the Israel Chemical Society (Israel)
- Division of Medicinal Chemistry of the Italian Chemical Society (Italy)
- Polish Society of Medicinal Chemistry (Poland)
- Division of Medicinal Chemistry of the Portuguese Chemical Society (Portugal)
- Medicinal Chemistry Section of the Russian Chemical Society, (Russia)
- Serbian Chemical Society, Division of Medicinal Chemistry (Serbia)
- Section for Medicinal Chemistry of the Slovenian Pharmaceutical Society (Slovenia)
- Sociedad Espanola de Quimica Terapeutica (Spain)
- Section for Medicinal Chemistry of the Swedish Pharmaceutical Society, (Sweden)
- Division of Medicinal Chemistry & Chemical Biology, Swiss Chemical Society (Switzerland)
- Division Medicinal Chemistry & Chemical Biology of the Netherlands (Netherlands)
- Turkish Association of Medicinal and Pharmaceutical Chemistry (Turkey)
- Society for Medicines Research (United Kingdom)
- The Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry (United Kingdom)

B. Relationships with Other Scientific Bodies:

1] The EFMC has signed Memoranda of Understanding with the following Scientific Bodies:

- Division of Medicinal Chemistry of the American Chemical Society (ACS-MEDI)
- Asian Federation for Medicinal Chemistry (AFMC)
- The Chinese Pharmaceutical Association (CPA)
- European Chemical Society (EuCheMS)
- The European Federation for Pharmaceutical Sciences (EUFEPS)
- The International Chemical Biology Society (ICBS)
- The Brazilian Society of Chemistry (SBQ)

C. EFMC-Schools

C.1] EFMC Certified Schools

-) European School on Medicinal Chemistry, Italy
-) SEQT Summer School, Spain
-) Swiss Course on Medicinal Chemistry, Switzerland
-) Swiss Summer School on Chemical Biology, Switzerland
-)Vienna Summer School, Vienna, Austria

C.2] EFMC Sponsored Schools

-)Summer School on Pharmaceutical Analysis, Rimini, Italy

D. Regulations of Awards

1] The Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology

§1) The W.Th. Nauta Award is established by the Dutch Foundation "Stichting Prof. Dr. W.Th. Nauta Fonds" from funds made available by Mrs. N.G. Nauta-Das for the memory of Prof. Dr. W.Th. Nauta. The Award will honour the memory of Prof. Dr. Wijbe Nauta whose activities have been very important for the advancement of Medicinal Chemistry in general and the development of international organisation structures in particular.

§2) The W.Th. Nauta Award will acknowledge outstanding results of scientific research in the field of Medicinal Chemistry and Chemical Biology obtained by scientists without restrictions regarding nationality. In exceptional cases the Award will acknowledge the achievements of a scientist, who has contributed predominantly in other ways to the advancement of Medicinal Chemistry, e.g. by fostering the cooperation between countries in this science.

§3) The Award will consist of a diploma, € 7.500, a lecture by the Award recipient. The level of the prize will depend on the economical conditions. The money will be provided by the W.Th. Nauta Foundation.

§4) The scientist whose work and/or activities complies with the description given under §2 of these regulations, qualifies for the Award.

§5) The Award will be given every second year and was started in 1992.

§6) The Executive Committee of the European Federation for Medicinal Chemistry (EFMC) is responsible for the final selection of the recipient, upon proposal by a special jury.

§7) A call for proposals to suggest nominees will be published before October of the year preceding the year in which the prize will be awarded in suitable scientific journals and by sending a call to scientific institutions and societies, including a poster. The prize will be presented during the biennial meeting of the EFMC, i.e. at the EFMC International Symposium on Medicinal Chemistry or during another appropriate meeting.

§8) The board of the “Stichting Prof.Dr. W.Th. Nauta Fonds” is responsible for the correct execution of these regulations and will act to the best of its knowledge in cases for which these regulations do not provide guidance.

2] UCB – Ehrlich Award for Excellence in Medicinal Chemistry

§ 1) The Award is established by UCB S.A., Pharma Sector, having its registered offices at 60, Allée de la Recherche, B-1070 Brussels, Belgium.

§ 2) The Award will acknowledge outstanding scientific research in the field of Medicinal Chemistry in its broadest sense.

§ 3) The Award will consist of a diploma, € 7.500, a lecture by the Award recipient, and travel expenses incidental to receiving the Award. Funding will be provided by UCB S.A., Pharma Sector.

§ 4) The Award shall be open to any Scientist whose work complies with the description given under §2 of these regulations, whose age does not exceed 50 years on January 1 of the year during which the Award is to be presented, and whose accomplishment has not yet been honoured by other EFMC awards.

§ 5) The Award will be given biennially, starting in 2002.

§ 6) The Executive Committee of the European Federation for Medicinal Chemistry (EFMC) is responsible for the final selection of the recipient upon proposal by the Award Nomination Committee.

§ 7) The Award Nomination Committee will consist of five members: the President of the EFMC, who will chair the Committee, and four additional members nominated by the EC after a proposal made by the EFMC President.

§ 8) A call for nominations will be published before October 1 of the year preceding the year in which the Award will be presented, in suitable scientific journals and by notifying key scientific institutions and societies. Nominations should consist of a letter proposing the candidate(s), a brief biographical sketch with a list of selected publications, and two supporting letters. The Award will be presented during the biennial meeting of the EFMC, i.e. at the EFMC International Symposium on Medicinal Chemistry, during which the recipient will be invited to give a presentation

§ 9) UCB S.A, Pharma Sector is responsible for the correct execution of these regulations and will act to the best of its knowledge and ability to resolve cases for which these regulations do not provide exact guidance.

3] Prous Institute – Overton and Meyer Award for New Technologies in Drug Discovery

§ 1) The Award is established by Prous Institute, having its registered offices at Calle Provenza, 388, 08025 Barcelona, Spain.

§ 2) The award encourages research and innovation in respect to the technological means used in the drug discovery field. The winner will be selected on account of his, or her discovery, evaluation and use of such technologies.

§ 3) The Award will consist of a diploma, € 7.500, a lecture by the Award recipient, and travel expenses incidental to receiving the Award. Funding will be provided by Prous Institute.

§ 4) The Award shall be open to any Scientist whose work complies with the description given under §2 of these regulations and whose accomplishment has not yet been honoured by other EFMC awards.

§ 5) The Award will be given biennially, starting in 2004.

§ 6) The Executive Committee of the European Federation for Medicinal Chemistry (EFMC) is responsible for the final selection of the recipient upon proposal by the Award Nomination Committee.

§ 7) The Award Nomination Committee will consist of five members: the President of the EFMC, who will chair the Committee, and four additional members nominated by the EC Committee after a proposal made by the EFMC President.

§ 8) A call for nominations will be published before October 1st of the year preceding the year in which the Award will be presented, in suitable scientific journals and by notifying key scientific institutions and societies. Nominations should consist of a letter proposing the candidate(s), a brief biographical sketch with a list of selected publications, and two supporting letters. The Award will be presented during the biennial meeting of the EFMC, i.e. at the EFMC International Symposium on Medicinal Chemistry, during which the recipient will be invited to give a presentation.

§ 9) Prous Institute is responsible for the correct execution of these regulations and will act to the best of its knowledge and ability to resolve cases for which these regulations do not provide exact guidance.

4] EFMC-WuXi AppTec Award for Excellence in Chemical Biology

§ 1) The award is established by WuXi AppTec (HongKong) Limited, having its registered offices at Unit C, 20/F., OfficePlus @ Mong Kok, No. 998 Canton Road, Kowloon, Hong Kong .

§ 2) The award will acknowledge outstanding scientific research in the field of Chemical Biology, as defined by the European Federation for Medicinal chemistry and Chemical Biology (EFMC).[1] Applicants should have a track record of significant research achievements in chemical biology during the last 10 years in terms of originality and significance of their research contributions.

§ 3) The award will consist of a diploma, € 7.500, a lecture by the award recipient, and travel expenses (capped at 2500€) incidental to receiving the Award. WuXi AppTec will provide funding for the award.

§ 4) The award shall be open to any scientist whose work complies with the description given under §2 of these regulations, whose career does not exceed 20 years after PhD on January 1st of the year during which the award is to be presented, and whose accomplishment has not yet been honoured by other EFMC awards.

§ 5) The award will be given biennially, starting in 2023.

§ 6) The Executive Committee of the EFMC is responsible for the final selection of the recipient upon

proposal by the Award Nomination Committee.

§ 7) The Award Nomination Committee will consist of five members: the President of the EFMC, who will chair the committee, and four additional members nominated by the EC after a proposal made by the EFMC President.

§ 8) A call for nominations will be published before October 1st of the year preceding the year in which the award will be presented, using established EFMC communication channels and by notifying relevant scientific institutions and societies. The first call will take place before October 1st, 2022. Nominations should consist of a letter (max. two pages) proposing the candidate(s), a brief biographical sketch with a list of selected publications, and two supporting letters. Self-nominations are also accepted.

§ 9) The award will be presented during the biennial EFMC International Symposium on Chemical Biology (EFMC-ISCB), during which the recipient will be invited to give a presentation.

E. Regulations of Prizes

1] The EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry

1.1] Prize Title

“The EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Industry”

2.2] Short description of the Prize

The prize was initiated by the former EFMC Industrial Liaison Committee (ILC) to acknowledge and recognize an outstanding young medicinal chemist or chemical biologist (≤ 12 years after PhD) working in industry within Europe. The Prize is given annually and consists of a diploma, € 1.000 and an invitation for a short presentation at an EFMC symposium.

3.3] Regulations for the prize.

§ 1) The Prize is established by the European Federation for Medicinal Chemistry and Chemical Biology (EFMC).

§ 2) The Prize will acknowledge and recognize an outstanding young medicinal chemist or chemical biologist (≤ 12 years after PhD) working in industry within Europe. The nominees should be a member of one of the EFMC National Adhering Organisation (NAO). In accordance with the EFMC core values of equal opportunities and inclusiveness; Maternity leaves, as well as leaves taken for health or private reasons are considered in the ≤ 12 years after PhD limit.

§ 3) The Prize will consist of a diploma, € 1.000, and a short presentation by the Prize recipient at a major EFMC symposium of the winning year (e.g. EFMC-ISMC or ASMC). Funding for the prize will be provided by the EFMC.

Two runners-up will also be identified and acknowledged. These runners-up will also receive a diploma and will be invited to attend the EFMC symposium and join the Prize celebrations. Registration expenses for the Prize winner and runners-up to attend the EFMC symposium will be paid for by the EFMC, but travel and accommodation expenses are expected to be paid for by each nominee's own industrial organisation.

§ 4) The Prize shall be open to any Scientist whose work complies with the description given under §2 of these regulations, who completed their PhD ten or less years ago from January 1st of

the year during which the Prize is to be presented, who is working in industry within Europe, and whose accomplishment has not yet been honoured by other EFMC awards.

§ 5) The Prize will be given annually, starting in 2010.

§ 6) The Prize Selection Committee will be appointed by the Executive Committee (EC) of EFMC, and will be chaired by an EC member. The Prize Selection Committee will select the winner and two 'runners up'. Members of the Prize Selection Committee will not participate in the review of any candidates from their own organisations, or of candidates with whom they have any relationship.

§ 7) A call for nominations will usually be published before October 1st of the year prior to the year in which the Prize will be presented, by notifying all member societies, and by advertising via the EFMC communication channels. All corporate members of the EFMC will also be given a direct notification of the Prize.

Nominations should be submitted by the candidate's supervisor and should consist of:

- a letter by the supervisor recommending the candidate, and stating that their organisation will cover costs of travel and accommodation if their candidate is selected as either the Prize winner or a runner-up.
- a brief CV of the candidate with a list of publications, patents & external presentations.
- abstract of potential oral presentation which, if successful, the candidate would present upon receipt of the Prize.

The letter of recommendation should look to highlight some of the candidate's key achievements to date and comment on their future potential. Example contributions that would be worthy of comment include:

- Participation in programs delivering NME or/and clinical candidates
- Implementation of new technologies or approaches with positive impact on the science of medicinal chemistry
- Active role in driving new science through academic collaborations
- Participation/leadership in working groups on topics related to science, such as technology assessment, target assessment, etc
- Positive impact beyond his/her own project on the broader scientific community (e.g. in own medicinal chemistry department and potentially beyond)

Nominations have to reach the Selection Committee before January 31st of the Prize year.

The Prize will be presented during a major symposium of the Prize year, i.e. at the EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) or the International Symposium on Advances in Synthetic and Medicinal Chemistry (ASMC), where the recipient will be invited to give a presentation.

§ 8) EFMC is responsible for the correct execution of these regulations and will act to the best of its knowledge and ability to resolve cases for which these regulations do not provide exact guidance.

2] The EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia

1.1] Prize Title

"The EFMC Prize for a Young Medicinal Chemist or Chemical Biologist in Academia"

2.2] Short description of the Prize

The prize was established by the European Federation for Medicinal Chemistry (EFMC) to acknowledge and recognize an outstanding young medicinal chemist or chemical biologist (≤ 12 years after PhD) working in academia within Europe. The Prize is given annually and consists of a diploma, € 1.000 and an invitation for a short presentation at an EFMC symposium.

3.3] Regulations for the Prize.

§ 1) The Prize is established by the European Federation for Medicinal Chemistry and Chemical Biology (EFMC).

§ 2) The Prize will acknowledge and recognize an outstanding young medicinal chemist and chemical biologist (≤ 12 years after PhD) working in academia within Europe. In accordance with the EFMC core values of equal opportunities and inclusiveness; Maternity leaves, as well as leaves taken for health or private reasons are considered in the ≤ 12 years after PhD limit.

§ 3) The Prize will consist of a diploma, € 1.000, and a short presentation by the Prize recipient at a major EFMC symposium of the winning year (e.g. EFMC-ISMC or ASMC). Funding for the prize will be provided by the EFMC.

Two runners-up will also be identified and acknowledged. These runners-up will also receive a diploma and will be invited to attend the EFMC symposium and join the Prize celebrations. Registration expenses for the Prize winner and runners-up to attend the EFMC symposium will be paid for by the EFMC.

§ 4) The Prize shall be open to any Scientist whose work complies with the description given under §2 of these regulations, and who meets the following criteria.

- a) The candidate completed his PhD ten or less years ago from January 1st of the year during which the Prize is to be presented.
- b) The candidate is on a career track at a University or an Academic Research Institute in Europe and the major part of his research has been carried out in Europe.
- c) The candidate has not yet been honoured by other EFMC awards.
- d) Candidates are expected to have a strong, international competitive publication record in journals ranked in the top quartile of the ISI categories related to medicinal chemistry.

§ 5) The Prize will be given annually, starting in 2010.

§ 6) The Prize Selection Committee will be appointed by the Executive Committee (EC) of EFMC, and will be chaired by an EC member. The Prize Selection Committee will select the winner and two 'runners up'. Members of the Prize Selection Committee will not participate in the review of any candidates from their own organisations, or of candidates with whom they have any relationship.

§ 7) A call for applications will usually be published before October 1st of the year prior to the year in which the Prize will be presented, by notifying all member societies, and by advertising via the EFMC communication channels. Applications should consist of:

- a one-page letter by the candidate including a short rationale for their application, indicating his/her 3 most important research achievements

- one page with his/her 5 most important publications with impact factor and number of citations. Furthermore, this should also contain the h-index for the complete publication list and the names and contact details of 3 referees who are familiar with the candidate's work.
- a brief CV of the candidate with a complete list of publications, patents and invited presentations.
- abstract of potential oral presentation which, if successful, the candidate would present upon receipt of the Prize.

Applications have to reach the Selection Committee before January 31st of the Prize year.

The Prize will be presented during a major symposium of the Prize year, i.e. at the EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC) or the International Symposium on Advances in Synthetic and Medicinal Chemistry (ASMC), where the recipient will be invited to give a presentation.

§ 8) EFMC is responsible for the correct execution of these regulations and will act to the best of its knowledge and ability to resolve cases for which these regulations do not provide exact guidance. The EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC)

§ 1) The series of conferences "EFMC International Symposium on Medicinal Chemistry" (EFMC-ISMC), have been organized since 1962. The European Federation for Medicinal Chemistry (EFMC) is the initiator and sponsor of this series of symposia, each of which is organized in a European city in collaboration with one or more EFMC National Adhering Organization/s (NAO).

§ 2) The organization of an EFMC-ISMC is commissioned on decision of the Council to one or more Adhering Organizations. Adhering Organizations may apply as organizers by sending a proposal to the EC. Upon selection the respective NAO(s) will have to sign a contract with EFMC.

§ 3) In order to guarantee a sustainable quality and corporate identity of the EFMC-ISMC, the meeting should be organized by a company which has a broad experience in organizing Medicinal Chemistry events and is well established in the Medicinal Chemistry Community. Thus the Executive Committee decided at its meeting in Copenhagen, June 7 2008, to appoint LDO Organisation for the organization of this and future EFMC-ISMCs.

§ 4) Financial Conditions

a) It is agreed between the parties that:

- (a) EFMC shall receive, as the official organizer of the ISMC, (i) 6% of the Registration Fees (hereafter the "6% Fee") paid by the participants and (ii) 8% of the Registration Fees (hereafter the "8% Fee") paid by commercial exhibitors.
- (b) If profits are deriving from the organisation of the ISMC (hereafter the "Profits"), LDO, the EFMC and the NAO(s) shall receive to the extent of respectively (i) 50% for LDO and (ii) 25% for EFMC and 25% for the NAO(s).

The Profits result from the difference between:

- (i) Income composed of the Registration Fees paid by the participants (commercial and non commercial) and subsidies paid by sponsors and/or other governmental or administrative authority if any or any other entity; and
- (ii) Charges composed of expenses incurred for the organisation borne by LDO and the NAO(s) and a commission paid to EFMC. This commission amounts to :
 - 6 % of the Registration Fees paid by the participants to the extent of the Forecasted Number of Participants;
 - 8% of the Registration Fees (including all extras) paid by commercial exhibitors

(c) In case of a financial loss due to not reaching the break-even number, EFMC agrees to give up the 6% Fee and the 8% Fee and LDO agrees to bear the financial loss in excess, if any.